Longeveron Inc. (LGVN): R&D Expense
$12.04M
Year ended 2025-12-31
$12.09M
Trailing 12 months to 2026-06-30
+8.7%
3-year compound annual growth
+35.1%
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $12.04M | +48.0% | 2026-03-17, From 2025-01-01 |
| 2024-12-31 | $8.14M | -10.2% | 2026-03-17, From 2024-01-01 |
| 2023-12-31 | $9.07M | -3.2% | 2025-02-28, From 2023-01-01 |
| 2022-12-31 | $9.37M | +32.1% | 2024-02-27, From 2022-01-01 |
| 2021-12-31 | $7.09M | +165.2% | 2023-03-14, From 2021-01-01 |
| 2020-12-31 | $2.67M | n/a | 2022-03-11, From 2020-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Longeveron Inc. (LGVN) | 2025-12-31 | $12.04M | +48.0% |
| Neuphoria Therapeutics Inc. (NEUP) | 2025-06-30 | $9.01M | -4.4% |
| Vistagen Therapeutics, Inc. (VTGN) | 2026-03-31 | $54.97M | +39.6% |
| IGC Pharma, Inc. (IGC) | 2025-03-31 | $3.65M | -3.1% |
| Northwest Biotherapeutics Inc (NWBO) | 2025-12-31 | $28.79M | -17.5% |
| Dare Bioscience, Inc. (DARE) | 2025-12-31 | $5.52M | -61.4% |
| Avenue Therapeutics, Inc. (ATXI) | 2025-12-31 | $1.04M | -84.4% |
| 60 Degrees Pharmaceuticals, Inc. (SXTP) | 2025-12-31 | $2.11M | -57.8% |
| Shattuck Labs, Inc. (STTK) | 2025-12-31 | $35.27M | -47.5% |
Compare LGVN, NEUP, VTGN, IGC side by side · Screen every company in Pharmaceutical Preparations ↗